Patients with chronic liver disease, including cirrhosis and varying degrees of hepatic dysfunction
Care Setting
Radiology departments performing hepatobiliary MRI with gadoxetic acid contrast
Key Highlights
Gadoxetate disodium-enhanced MRI improves detection of advanced and borderline HCC lesions by enhancing lesion-to-liver contrast.
Patients with cirrhosis, especially Child–Pugh class B or C, often exhibit poor liver-to-spleen contrast (LSC ≤ 1.5) on standard 20-minute hepatobiliary phase imaging.
Super delayed phase (SDP) imaging at 60–120 minutes post-contrast administration may improve liver contrast in patients with initially poor LSC, potentially enhancing nodule visibility.
Guideline-Based Recommendations
Diagnosis
Use gadoxetate disodium-enhanced MRI for noninvasive diagnosis of HCC in at-risk patients.
Assess liver-to-spleen contrast (LSC) at 20 minutes post-contrast to evaluate adequacy of hepatobiliary phase imaging.
Management
Consider additional delayed imaging (super delayed phase) between 60 and 120 minutes post-contrast in patients with inadequate liver contrast (LSC ≤ 1.5) at 20 minutes.
Obtain patient consent prior to extended imaging due to increased examination time.
Monitoring & Follow-up
Quantitatively measure LSC in both standard (20 min) and super delayed phases to assess improvement in liver parenchymal enhancement.
Monitor for changes in nodule visibility with additional delayed imaging.
Risks
Extended imaging time may increase patient burden and resource utilization.
Poor liver function (Child–Pugh B or C) may limit contrast uptake and image quality despite delayed imaging.
Patient & Prescribing Data
Patients undergoing gadoxetic acid-enhanced MRI for evaluation of liver lesions, particularly those with chronic liver disease and impaired hepatic function.
Standard dose of 0.025 mmol/kg gadoxetic acid administered intravenously at 1 mL/s with 20 mL saline flush; additional delayed imaging recommended selectively based on initial liver contrast assessment.
Clinical Best Practices
Perform initial hepatobiliary phase imaging at 20 minutes post-contrast injection to evaluate liver parenchymal enhancement.
Use liver-to-spleen contrast ratio (LSC) with a threshold of 1.5 to determine adequacy of imaging contrast.
Implement super delayed phase imaging at 60–120 minutes post-injection in patients with poor initial LSC to improve diagnostic confidence.
Ensure careful placement of regions of interest (ROIs) in liver and spleen avoiding lesions and vascular structures for accurate LSC measurement.
Obtain patient consent for extended imaging due to increased examination duration and potential patient burden.
